BioNTech shows strong 3 year follow up results on T cell Vaccine to increase remission and survival time in patients with pancreatic cancer

- Three-year follow-up data from a Phase 1 trial showed autogene cevumeran induced T cell responses and delayed tumor recurrence in patients with pancreatic cancer (PDAC) - A Phase 2 trial with autogene cevumeran is enrolling patients with resected PDAC in the US and globally due to the high medical need for treatment options in PDAC - Autogene cevumeran is developed by BioNTech and Genentech, and is the lead candidate in BioNTech's mRNA-based cancer vaccine platform iNeST, currently being evaluated in Phase 2 trials for PDAC, melanoma, and colorectal cancer - The Phase 1 trial evaluated the safety of autogene cevumeran in combination with atezolizumab and chemotherapy in patients with resected PDAC - The Phase 2 trial will compare autogene cevumeran with standard care in patients with PDAC, and is enrolling patients in the US with plans for global sites - PDAC has a low survival rate, high recurrence rates, and limited treatment options, creating an unmet medical need for new therapies - Autogene cevumeran is an individualized cancer therapy tailored to a patient's tumor, encoding neoantigens to help the immune system recognize and eliminate cancer cells - BioNTech and Genentech are collaborating to develop autogene cevumeran and advancing the field of personalized cancer medicine